Vyriad

Vyriad, based in Rochester, the United States, is a biotechnology company. Vyriad engineers targeted viral platforms for genetic therapies, developing in vivo gene therapies, genome editing and oncolytic virotherapies delivered through engineered virus vectors, including VSV and measles virus platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, head and neck squamous cell carcinoma, colorectal cancer, non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT04291105 (Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients), plans to enrol 87 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.